Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07851220) titled 'A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy' on Sept. 25.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Amgen

Condition: Glomerulonephritis, Membranous

Intervention: Drug: Inebilizumab

Recruitment Status: Recruiting

Phase: Phase 3

Date of First Enrollment: October 1, 2026

Target Sample Size: 159

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/study/NCT07851220

Disclaimer: Curated by HT Syndica...